DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer

• Status: Terminated
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this trial is to study DPPE combined with epirubicin and cyclophosphamide in patients with metastatic and/or recurrent breast cancer who may have received previous hormone treatment but have not had exposure to anthracycline treatment. Stratification allocation will be within the following subgroups:

1. Prior cytotoxic treatment;

2. Estrogen receptor status;

3. ECOG performance status;

4. Number of cycles of chemotherapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: YM BioSciences
• Treatments: Cyclophosphamide; Epirubicin

Criteria

Inclusion Criteria:

• Histological proof of breast cancer

• Documented evidence of metastatic and/or recurrent breast cancer

• Presence of at least one bi-dimensional or uni-dimensional lesion

• ECOG status 0, 1 or 2

• Quality of life